EN DE
Watch Vivozon Healthcare Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vivozon Healthcare Inc (082800) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Vivozon Healthcare Inc stock KRW 2,179, price KRW 3,000, that is 27.4% below the price, quality 29 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7082800004

VH Vivozon Healthcare Inc logo Thin data Nov 16, 2026

Vivozon Healthcare Inc

082800 · KQ

Expensive (fair value 27% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Mixed Growth (revenue 5y +6.4 %/yr in KRW) 
Fair value 2,179 KRW · Overvalued 
Quality 29/100 
Falling price (downtrend) 
Loss-making · -126.7% net margin (TTM) 
Negative free cash flow 
Trails peers (1/9) 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Vivozon Healthcare Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

10,636 KRW 1,956 KRW Fair Value 2,179 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,956 KRW – 10,636 KRW · fair‑value band 1,634 KRW – 2,723 KRW · the 3,000 KRW price screens above the 2,179 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Vivozon Healthcare in your weekly email

Every Wednesday you see whether Vivozon Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vivozon Pharmaceutical Co., Ltd. researches, develops, produces, and sells LED products primarily in South Korea. The company offers LED packages for interior, general, indoor, decorative, and automotive lighting, as well as display applications.

Show moreShow less

It also provides LED set linear lamps, including panel lamps, down lights, and flood lights for residential, commercial, and industrial structures, as well as lights for parking lots.

In addition, the company operates Echo House, a lighting show room that sells LED florescent lamps, LED flat lamps, LED PAR lamps, LED bulb lamps, and home LED lightings.

The company was formerly known as Vivozon Healthcare, Inc. and changed its name to Vivozon Pharmaceutical Co., Ltd. in November 2022. Vivozon Pharmaceutical Co., Ltd. was founded in 2002 and is based in Yongin, South Korea.

Stock analysis

Vivozon Healthcare Inc (082800) currently trades at 3,000 KRW, while our estimate is 2,179 KRW, 27% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,634 KRW (bear) to 2,723 KRW (bull), the price of 3,000 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vivozon Healthcare Inc reported revenue of 59.3B KRW in FY2025 versus 57.7B KRW in FY2021, a compound +0.7%/yr. Reported net income was −32.4B KRW in FY2025.

Key figures

Market cap 178B KRW (≈ $133M) Micro · P/S ratio 2.97 · Net margin −127% · Return on equity −1,315% · Return on assets (EBIT) −8.5% (5-year average) · Operating margin −37.7% · Revenue (TTM) 59.9B KRW · Revenue growth (YoY) +8.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 39% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −38% fair-value upside, at −27%, 082800 screens cheaper than that median.

Fair Value

Bear 1,634 KRW Fair Value 2,179 KRW Bull 2,723 KRW
Price 3,000 KRW · Downside -27.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 35
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 33
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 12
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 12/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−32.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2020 (pandemic). Over 10 years: −4.1% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−46.6% (2020) → −32.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

082800 screens overvalued: fair value 27% below the price. Compare with ST Pharm Co →

Compare Vivozon Healthcare Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 58 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −27.4% · Below median
Profitability
Return on assets −19.6% · Bottom 25%
Net margin (12 months) −126.7% · Bottom 25%
Operating margin (12 months) −37.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 8.5% · Below median

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 2.45× · Priciest 25%
P/S (12 months) 2.97× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 12
FUTURE (revenue growth)43 · sector 68
PAST (return on equity)0 · sector 24
HEALTH (low debt)100 · sector 98
DIVIDEND (yield)0 · sector 26

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,430 KRW 47,019 KRW +142% vs 082800
DongKook Pharmaceutical Co 086450 23,050 KRW 28,372 KRW +23% vs 082800
VIKRAMTH VIKRAMTH ₹319.80 ₹352.17 +10% vs 082800
ST Pharm Co 237690 71,200 KRW 61,182 KRW −14% vs 082800
Oscotec Inc 039200 34,250 KRW 21,262 KRW −38% vs 082800
NatureCell Co 007390 21,950 KRW 11,176 KRW −49% vs 082800
Mezzion Pharma Co 140410 64,500 KRW 31,450 KRW −51% vs 082800
BINEX Co 053030 6,680 KRW 1,844 KRW −72% vs 082800
Caregen Co 214370 27,900 KRW 5,414 KRW −81% vs 082800
SHUKRAPHAR SHUKRAPHAR ₹82.24 ₹9.14 −89% vs 082800

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vivozon Healthcare Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vivozon Healthcare Inc Fair Value". https://www.fairvalue-calculator.com/stock/082800

Frequently asked questions

Is Vivozon Healthcare Inc (082800) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 2,179 KRW versus a price of 3,000 KRW, about 27% lower (overvalued).
What is the fair value of 082800?
Our estimate for Vivozon Healthcare Inc is 2,179 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 3,000 KRW.
What is the quality score of 082800?
Vivozon Healthcare Inc has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivozon Healthcare Inc (082800)?
Our calculated price target is the estimate of 2,179 KRW (as of Nov 16, 2026). Cautious scenario 1,634 KRW, optimistic scenario 2,723 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vivozon Healthcare Inc stock forecast for 2026?
Our estimate puts fair value at 2,179 KRW, about 27% lower versus a price of 3,000 KRW (overvalued). Cautious scenario 1,634 KRW, optimistic scenario 2,723 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Vivozon Healthcare Inc (082800)?
Vivozon Healthcare Inc reported trailing-twelve-month revenue of about 59.9B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Vivozon Healthcare Inc (082800)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivozon Healthcare Inc it is 2,179 KRW per share (as of Nov 16, 2026), against a price of 3,000 KRW.
Is Vivozon Healthcare Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 082800 trades above its calculated fair value: price 3,000 KRW, fair value 2,179 KRW, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 082800?
No. The price is what the market pays today (3,000 KRW); the fair value is what the company's own numbers justify (2,179 KRW). For Vivozon Healthcare Inc the two are 821.32 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivozon Healthcare Inc worth?
The market values Vivozon Healthcare Inc at about 178B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 3,000 KRW; our models calculate a fair value of 2,179 KRW per share.
What do the bullish and bearish scenarios say about 082800?
Our models span a range for Vivozon Healthcare Inc: cautious scenario 1,634 KRW, base 2,179 KRW, optimistic 2,723 KRW per share (as of Nov 16, 2026, price 3,000 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 082800 from its 52-week high?
Vivozon Healthcare Inc trades at 3,000 KRW, about 48% below its 52-week high of 5,750 KRW and 39% above the low of 2,155 KRW (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 2,179 KRW is for.
Which stocks are comparable to Vivozon Healthcare Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivozon Healthcare Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 3,000 KRW, calculated fair value 2,179 KRW (−27%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Vivozon Healthcare Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivozon Healthcare Inc (082800)?
The closing price on Nov 16, 2026 was 3,000 KRW. Our estimate is 2,179 KRW, about 27% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivozon Healthcare Inc right now?
The price sits above even our optimistic bull case (2,723 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vivozon Healthcare Inc

How large is the market capitalisation of Vivozon Healthcare Inc (082800)?
The market capitalisation of Vivozon Healthcare Inc is 178B KRW (≈ $133M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vivozon Healthcare Inc (082800)?
The price-to-sales ratio of Vivozon Healthcare Inc is 2.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Vivozon Healthcare Inc (082800)?
The net margin of Vivozon Healthcare Inc is −127% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vivozon Healthcare Inc (082800)?
The return on equity (ROE) of Vivozon Healthcare Inc is −1,315% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vivozon Healthcare Inc (082800)?
On an EBIT basis the return on assets of Vivozon Healthcare Inc is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivozon Healthcare Inc (082800)?
The operating margin of Vivozon Healthcare Inc is −37.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivozon Healthcare Inc (082800)?
Revenue at Vivozon Healthcare Inc is growing 8.5% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Vivozon Healthcare Inc (082800) generate?
The free cash flow of Vivozon Healthcare Inc is −9.1B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivozon Healthcare Inc (082800) carry?
The net debt of Vivozon Healthcare Inc is 37.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vivozon Healthcare Inc in the live analysis

One click puts Vivozon Healthcare Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.